Anti-Heparanase Aptamers as Potential Diagnostic and Therapeutic Agents for Oral Cancer

Heparanase is an endoglycosidase enzyme present in activated leucocytes, mast cells, placental tissue, neutrophils and macrophages, and is involved in tumour metastasis and tissue invasion. It presents a potential target for cancer therapies and various molecules have been developed in an attempt to inhibit the enzymatic action of heparanase. In an attempt to develop a novel therapeutic with an associated diagnostic assay, we have previously described high affinity aptamers selected against heparanase. In this work, we demonstrated that these anti-heparanase aptamers are capable of inhibiting tissue invasion of tumour cells associated with oral cancer and verified that such inhibition is due to inhibition of the enzyme and not due to other potentially cytotoxic effects of the aptamers. Furthermore, we have identified a short 30 bases aptamer as a potential candidate for further studies, as this showed a higher ability to inhibit tissue invasion than its longer counterpart, as well as a reduced potential for complex formation with other non-specific serum proteins. Finally, the aptamer was found to be stable and therefore suitable for use in human models, as it showed no degradation in the presence of human serum, making it a potential candidate for both diagnostic and therapeutic use.

[1]  Ying-Fon Chang,et al.  Tenascin-C Aptamers Are Generated Using Tumor Cells and Purified Protein* , 2001, The Journal of Biological Chemistry.

[2]  A D Ellington,et al.  Aptamers as therapeutic and diagnostic reagents: problems and prospects. , 1997, Current opinion in chemical biology.

[3]  C. Ferreira,et al.  DNA Aptamers That Bind to MUC1 Tumour Marker: Design and Characterization of MUC1-Binding Single-Stranded DNA Aptamers , 2006, Tumor Biology.

[4]  Sheela M. Waugh,et al.  2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.

[5]  D. Adams,et al.  Leucocyte-endothelial interactions and regulation of leucocyte migration , 1994, The Lancet.

[6]  I. Vlodavsky,et al.  Molecular properties and involvement of heparanase in cancer progression and normal development. , 2001, Biochimie.

[7]  R. Goldberg,et al.  Heparanase in inflammation and inflammation‐associated cancer , 2013, The FEBS journal.

[8]  M. Yanagishita,et al.  Expression of heparanase in oral cancer cell lines and oral cancer tissues. , 2001, Oral oncology.

[9]  Tibor Hianik,et al.  Detection of aptamer-protein interactions using QCM and electrochemical indicator methods. , 2005, Bioorganic & medicinal chemistry letters.

[10]  M. Sodeoka,et al.  Structure-based design of a selective heparanase inhibitor as an antimetastatic agent. , 2004, Molecular cancer therapeutics.

[11]  S. Missailidis,et al.  Interactions of aptamers with sera albumins. , 2012, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[12]  J. Kiel,et al.  Anti-Francisella tularensis DNA aptamers detect tularemia antigen from different subspecies by Aptamer-Linked Immobilized Sorbent Assay , 2006, Laboratory Investigation.

[13]  T. Salo,et al.  A novel organotypic model mimics the tumor microenvironment. , 2009, The American journal of pathology.

[14]  R. Parekh,et al.  Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. , 2003, The Biochemical journal.

[15]  N. Janjić,et al.  Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. , 1999, The American journal of pathology.

[16]  S. Missailidis,et al.  A fluorescent spectroscopy and modelling analysis of anti-heparanase aptamers-serum protein interactions. , 2013, Journal of photochemistry and photobiology. B, Biology.

[17]  M. Price,et al.  Selection of aptamers with high affinity and high specificity against C595, an anti-MUC1 IgG3 monoclonal antibody, for antibody targeting. , 2005, Journal of immunological methods.

[18]  P. Brenchley,et al.  Development of Novel Single-Stranded Nucleic Acid Aptamers against the Pro-Angiogenic and Metastatic Enzyme Heparanase (HPSE1) , 2012, PloS one.

[19]  T. Peretz,et al.  Site-directed Mutagenesis, Proteolytic Cleavage, and Activation of Human Proheparanase* , 2005, Journal of Biological Chemistry.

[20]  Manfred Kansy,et al.  Predicting plasma protein binding of drugs: a new approach. , 2002, Biochemical pharmacology.

[21]  M Yarus,et al.  Diversity of oligonucleotide functions. , 1995, Annual review of biochemistry.

[22]  J. Lakowicz.  Principles of fluorescence spectroscopy , 1983 .

[23]  O. Pappo,et al.  Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis , 1999, Nature Medicine.

[24]  J. M. Healy,et al.  First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers , 2007, Circulation.

[25]  T. Nemoto,et al.  Loss of Syndecan‐1 and Increased Expression of Heparanase in Invasive Esophageal Carcinomas , 2001, Japanese journal of cancer research : Gann.

[26]  Misako Sato,et al.  Heparanase: A Key Enzyme in Invasion and Metastasis of Gastric Carcinoma , 2002, Modern Pathology.

[27]  D. Boudreau,et al.  Protein Detecting Arrays Based on Cationic Polythiophene–DNA‐Aptamer Complexes , 2006 .

[28]  C. Vargeese,et al.  Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. , 1995, Biochemistry.

[29]  G. Jayson,et al.  Hypoxia Increases Heparanase-Dependent Tumor Cell Invasion, Which Can Be Inhibited by Antiheparanase Antibodies , 2004, Cancer Research.

[30]  T. Salo,et al.  Type I and III collagen degradation products in serum predict patient survival in head and neck squamous cell carcinoma. , 2012, Oral oncology.

[31]  Ying-Fon Chang,et al.  Tumor targeting by an aptamer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  R. Hershkoviz,et al.  Molecular behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH , 1995, The Journal of experimental medicine.

[33]  I. Cohen,et al.  Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. , 1992, Invasion & metastasis.

[34]  G. Nicolson,et al.  Human heparanase: a molecular determinant of brain metastasis. , 2001, Advances in enzyme regulation.

[35]  Georgia Sotiropoulou,et al.  One round of SELEX for the generation of DNA aptamers directed against KLK6 , 2012, Biological chemistry.

[36]  Joseph Wang,et al.  Label-free bioelectronic detection of aptamer–protein interactions , 2005 .

[37]  M. Famulok,et al.  Aptamers as tools in molecular biology and immunology. , 1999, Current topics in microbiology and immunology.

[38]  H. Friess,et al.  The human endo-glycosidase heparanase is over-expressed in primary and metastatic pancreatic cancer , 2001 .

[39]  L. McGown,et al.  Affinity capture and detection of immunoglobulin E in human serum using an aptamer-modified surface in matrix-assisted laser desorption/ionization mass spectrometry. , 2007, Analytical chemistry.

[40]  B. Sullenger,et al.  Generation of species cross-reactive aptamers using "toggle" SELEX. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  Yi Lu,et al.  Reversible cell-specific drug delivery with aptamer-functionalized liposomes. , 2009, Angewandte Chemie.

[42]  Motowo Nakajima,et al.  Expression of three extracellular matrix degradative enzymes in bladder cancer , 2001, International journal of cancer.

[43]  I. Vlodavsky,et al.  Heparin, heparan sulfate and heparanase in inflammatory reactions , 2009, Thrombosis and Haemostasis.

[44]  Benito Casu,et al.  Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. , 2007, Current pharmaceutical design.

[45]  N. Fiotti,et al.  Aptamers as targeting delivery devices or anti-cancer drugs for fighting tumors. , 2013, Current drug metabolism.

[46]  Michael Musheev,et al.  Non-SELEX selection of aptamers. , 2006, Journal of the American Chemical Society.

[47]  C. Pisano,et al.  Significance of Heparanase in Cancer and Inflammation , 2012, Cancer Microenvironment.

[48]  I. Vlodavsky,et al.  Substrate Specificity of Heparanases from Human Hepatoma and Platelets* , 1998, The Journal of Biological Chemistry.

[49]  R. Baker,et al.  Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis , 1999, Nature Medicine.

[50]  M. Morra,et al.  Assessment of inner filter effect corrections in fluorimetry , 1991 .

[51]  P. Gattuso,et al.  Heparanase-1 expression is associated with the metastatic potential of breast cancer. , 2002, Surgery.

[52]  R. Heinrikson,et al.  Heterodimer formation is essential for heparanase enzymatic activity. , 2003, Biochemical and biophysical research communications.

[53]  T. Eberlein,et al.  T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Chao Zeng,et al.  Heparanase overexpression participates in tumor growth of cervical cancer in vitro and in vivo , 2013, Medical Oncology.

[55]  A. Purushothaman,et al.  Heparanase Regulates Secretion, Composition, and Function of Tumor Cell-derived Exosomes*♦ , 2013, The Journal of Biological Chemistry.

[56]  Kemin Wang,et al.  Electrochemical detection of thrombin based on aptamer and ferrocenylhexanethiol loaded silica nanocapsules. , 2011, Biosensors & bioelectronics.

[57]  L. Kjellén,et al.  Regulated Diversity of Heparan Sulfate* , 1998, The Journal of Biological Chemistry.

[58]  T. Peretz,et al.  Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. , 2002, Seminars in cancer biology.

[59]  Z. Fuks,et al.  Role of Heparanase in Platelet and Tumor Cell Interactions with the Subendothelial Extracellular Matrix , 1987, Seminars in thrombosis and hemostasis.

[60]  T. Peretz,et al.  Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. , 2000, The American journal of pathology.

[61]  D. Patel,et al.  Adaptive recognition by nucleic acid aptamers. , 2000, Science.

[62]  R. Palmer,et al.  Modification of thiol functionalized aptamers by conjugation of synthetic polymers. , 2010, Bioconjugate chemistry.

[63]  L. McGown,et al.  Aptamer-enhanced laser desorption/ionization for affinity mass spectrometry. , 2004, Analytical chemistry.

[64]  L. Garraway,et al.  A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma , 2014, Investigational New Drugs.

[65]  H. Friess,et al.  Heparanase expression in primary and metastatic pancreatic cancer. , 2001, Cancer research.

[66]  F. Zunino,et al.  The potential of heparanase as a therapeutic target in cancer. , 2014, Biochemical pharmacology.

[67]  J. Bennett,et al.  Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor. , 2005, Bioorganic & medicinal chemistry letters.